Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)

doi:10.4251/wjgo.119136

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(21)

(0)

(266)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 119136
Published online Jul 15, 2026. doi: 10.4251/wjgo.119136

Table 3 Five-year median time of overall survival and progression-free survival in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma with different treatment modalities, median (interquartile range) or mean ± SD

Prognosis	RFA (n = 40)	LR (n = 30)	Combined (n = 32)	H/F	P value
OS (day)	1373.5 (1191.0, 1559.8)	1782.5 (1499.2, 2132.5)	1455.0 (1238, 2194.8)	10.96	0.004
PFS (day)	1164.5 ± 422.1	1704.4 ± 569.8	1573.9 ± 581.7	10.49	< 0.001

LR: Liver resection; RFA: Radiofrequency ablation; OS: Overall survival; PFS: Progression-free survival; H: H-statistic; F: F-statistic.

Full Size Table

Citation: Zheng W, Lv P, Zhu Q, Zhang QL, Yin GG, Chen WG. Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World J Gastrointest Oncol 2026; 18(7): 119136
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/119136.htm
DOI: https://dx.doi.org/10.4251/wjgo.119136

Zheng W, Lv P, Zhu Q, Zhang QL, Yin GG, Chen WG. Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World J Gastrointest Oncol 2026; 18(7): 119136 [DOI: 10.4251/wjgo.119136]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.